Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$67.70
-$3.36(-4.36%)
At close: 4:00 PM EST
$67.70
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $94.07
Previous CloseN/A
Volume227.93K
Average Volume (3M)887.64K
Market Cap
$3.91B
Enterprise Value$3.89B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Feb 26, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding57,822,872
10 Day Avg. Volume940,139
30 Day Avg. Volume887,641
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)9.03
Price to Sales (P/S)38.06
P/FCF Ratio-42.39
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$113.46Price Target Upside67.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial And Approval MomentumAnalyst expectations of BLA acceptance with priority review combined with established manufacturing capacity and wide treatment-center availability support the potential for a strong commercial launch for anito-cel.
Regulatory GuidanceFDA draft guidance endorsing minimal residual disease negativity and complete response as acceptable primary endpoints could accelerate approval pathways for multiple myeloma CAR-T therapies, supporting a faster time to market for anito-cel.
Safety DifferentiationReported absence of delayed neurotoxicity and low rates of severe cytokine release syndrome or neurotoxicity position anito-cel with a differentiated safety profile that may encourage physician uptake and use in earlier treatment lines.
Bears Say
Addressable Market LimitationsA small real-world population that fits the teclistamab plus daratumumab study criteria suggests limited immediate uptake for similar regimens, which may constrain overall market growth dynamics in the near term.
Competitive Pressure From BispecificsStrong clinical data for BCMA bispecific antibodies could capture market share and exert pricing and access pressure on CAR-T therapies, challenging anito-cel's commercial opportunity.
Trial Population RepresentativenessLow prior exposure to anti-CD38 therapy in key bispecific trials raises concerns about how well those trial outcomes translate to the typical second- and third-line multiple myeloma population, complicating competitive comparisons.
Arcellx Inc News
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.86 and its highest was $94.07 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $3.91B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Feb 26, 2026 which is in 32 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Nov 05, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.007.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -1.03.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 57,822,872 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went up 0.788%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$113.46 (67.59% Upside)
$113.46 (67.59% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.53%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$113.46
▲(67.59% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---